Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1973 1
1974 2
1976 2
1977 1
1978 2
1979 3
1980 2
1981 1
1982 5
1983 2
1984 6
1985 7
1986 8
1987 3
1988 5
1989 9
1990 10
1991 10
1992 11
1993 18
1994 20
1995 11
1996 22
1997 21
1998 14
1999 22
2000 28
2001 20
2002 18
2003 34
2004 30
2005 15
2006 21
2007 24
2008 21
2009 26
2010 34
2011 36
2012 37
2013 39
2014 46
2015 51
2016 48
2017 67
2018 62
2019 42
2020 61
2021 48
2022 59
2023 63
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

1,031 results

Results by year

Filters applied: . Clear all
Page 1
Glofitamab CD20-TCB bispecific antibody.
Minson A, Dickinson M. Minson A, et al. Leuk Lymphoma. 2021 Dec;62(13):3098-3108. doi: 10.1080/10428194.2021.1953016. Epub 2021 Jul 15. Leuk Lymphoma. 2021. PMID: 34263696 Review.
Phase 1 monotherapy and combination data demonstrate clear activity in heavily treated aggressive and indolent B-cell lymphoma, including >50% complete responses at the recommended phase 2 dose. ...Glofitamab appears to be a welcome addition to the …
Phase 1 monotherapy and combination data demonstrate clear activity in heavily treated aggressive and indolent B-cell lymph …
Blinatumomab: a historical perspective.
Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Nagorsen D, et al. Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Pharmacol Ther. 2012. PMID: 22940266 Review.
For decades, chemotherapy has been the backbone for the treatment of patients with B cell malignancies. Depending on the individual disease, monoclonal antibodies, irradiation and/or hematopoietic stem cell transplantation are added. ...Here, we review how blinatumo …
For decades, chemotherapy has been the backbone for the treatment of patients with B cell malignancies. Depending on the indiv …
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.
Teachey DT, Pui CH. Teachey DT, et al. Lancet Oncol. 2019 Mar;20(3):e142-e154. doi: 10.1016/S1470-2045(19)30031-2. Lancet Oncol. 2019. PMID: 30842058 Free PMC article. Review.
Third, T-cell ALL blasts are generally more resistant to conventional chemotherapeutic drugs than are B-cell ALL blasts. Finally, patients with B-cell ALL are more amendable to available targeted therapies, such as Philadelphia chromosome-positive and …
Third, T-cell ALL blasts are generally more resistant to conventional chemotherapeutic drugs than are B-cell ALL blasts. Final …
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.
Brivio E, Baruchel A, Beishuizen A, Bourquin JP, Brown PA, Cooper T, Gore L, Kolb EA, Locatelli F, Maude SL, Mussai FJ, Vormoor-Bürger B, Vormoor J, von Stackelberg A, Zwaan CM. Brivio E, et al. Eur J Cancer. 2022 Mar;164:1-17. doi: 10.1016/j.ejca.2021.12.029. Epub 2022 Feb 1. Eur J Cancer. 2022. PMID: 35121370 Free article. Review.
Bispecific and antibody-drug conjugates targeting CD19 and CD22 (blinatumomab and inotuzumab ozogamicin) play an important role in the treatment of relapsed and refractory B-cell precursor acute lymphoblastic leukaemia (BCP-ALL); antibodies targeting CD123 and CD38 …
Bispecific and antibody-drug conjugates targeting CD19 and CD22 (blinatumomab and inotuzumab ozogamicin) play an important role in the treat …
Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
Davis K, Sheikh T, Aggarwal N. Davis K, et al. Semin Diagn Pathol. 2023 May;40(3):202-215. doi: 10.1053/j.semdp.2023.04.003. Epub 2023 Apr 9. Semin Diagn Pathol. 2023. PMID: 37120350 Review.
Tremendous strides have been made in the molecular and cytogenetic classification of acute lymphoblastic leukemia based on gene expression profiling data, leading to an expansion of entities in the recent International Consensus Classification (ICC) of myeloid neoplasms an …
Tremendous strides have been made in the molecular and cytogenetic classification of acute lymphoblastic leukemia based on gene expre …
Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS, Selemon H, Elton SM, Parinandi NL. Elton TS, et al. Gene. 2013 Dec 10;532(1):1-12. doi: 10.1016/j.gene.2012.12.009. Epub 2012 Dec 14. Gene. 2013. PMID: 23246696 Review.
MicroRNAs (miRNAs), a family of small nonprotein-coding RNAs, play a critical role in posttranscriptional gene regulation by acting as adaptors for the miRNA-induced silencing complex to inhibit gene expression by targeting mRNAs for translational repression and/or cleavage. miR- …
MicroRNAs (miRNAs), a family of small nonprotein-coding RNAs, play a critical role in posttranscriptional gene regulation by acting as adapt …
Marginal zone lymphomas.
Zucca E, Rossi D, Bertoni F. Zucca E, et al. Hematol Oncol. 2023 Jun;41 Suppl 1:88-91. doi: 10.1002/hon.3152. Hematol Oncol. 2023. PMID: 37294969 Review.
The three main types of marginal zone lymphoma (MZL), recognized by the current lymphoma classifications are the extranodal MZL of mucosa-associated lymphoid tissue, the splenic MZL, and the nodal MZL. ...However, they differ in the presence of recurrent translocati …
The three main types of marginal zone lymphoma (MZL), recognized by the current lymphoma classifications are the extranodal MZ …
Hepatic Lymphoma Diagnosis.
Choi WT, Gill RM. Choi WT, et al. Surg Pathol Clin. 2018 Jun;11(2):389-402. doi: 10.1016/j.path.2018.02.003. Epub 2018 Mar 21. Surg Pathol Clin. 2018. PMID: 29751882 Review.
Systemic hematopoietic disorders may present on liver biopsy, and rare cases of primary hepatic lymphoma (PHL) may be encountered. Hepatopathologists must be familiar with the full spectrum of hematopoietic disorders involving the liver and be prepared to exclude benign mi …
Systemic hematopoietic disorders may present on liver biopsy, and rare cases of primary hepatic lymphoma (PHL) may be encountered. He …
Modern Classification and Management of Pediatric B-cell Leukemia and Lymphoma.
Kovach AE, Raca G. Kovach AE, et al. Surg Pathol Clin. 2023 Jun;16(2):249-266. doi: 10.1016/j.path.2023.01.001. Epub 2023 Mar 8. Surg Pathol Clin. 2023. PMID: 37149359 Review.
Although pediatric hematopathology overlaps with that of adults, certain forms of leukemia and lymphoma, and many types of reactive conditions affecting the bone marrow and lymph nodes, are unique to children. As part of this series focused on lymphomas, this articl …
Although pediatric hematopathology overlaps with that of adults, certain forms of leukemia and lymphoma, and many types of rea …
B-cell neoplasms and Hodgkin lymphoma in the spleen.
Geyer JT, Prakash S, Orazi A. Geyer JT, et al. Semin Diagn Pathol. 2021 Mar;38(2):125-134. doi: 10.1053/j.semdp.2020.08.002. Epub 2020 Aug 10. Semin Diagn Pathol. 2021. PMID: 32839024 Review.
B-cell lymphoma of spleen may be primary (most commonly splenic diffuse large B-cell lymphoma) or secondary (typically low-grade non-Hodgkin lymphoma). ...This review article describes the clinicopathologic characteristics of all t …
B-cell lymphoma of spleen may be primary (most commonly splenic diffuse large B-cell lymphoma) or …
1,031 results